News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)

Study Status:

Closed for enrollment

Contact Information:

(956) 362-8047

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary efficacy endpoint is the histologic response defined as a subject achieving an improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis score) and no worsening of steatohepatitis (defined as no increase in NAS for ballooning, inflammation, or steatosis) after 48 weeks of treatment with aldafermin or matched placebo

Information: 

Principal Investigator
Fernando Membreno, MD
Co-PI
Guillermo Duran
Sponsor
NGM Biopharmaceuticals, Inc.
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram